Skip to main content

Primary Immune Deficiency: Patients' Preferences for Replacement Immunoglobulin Therapy.

Publication ,  Journal Article
Gonzalez, JM; Ballow, M; Fairchild, A; Runken, MC
Published in: Front Immunol
2022

PURPOSE: Immunoglobulin (Ig) replacement therapy is an important life-saving treatment modality for patients with primary antibody immune deficiency disorders (PAD). IVIG and SCIg are suitable alternatives to treat patients with PAD but vary in key ways. Existing evidence on patient preferences for Ig treatments given the complexities associated with IVIG and SCIg treatment is limited and fails to account for variations in preferences across patients. For this reason, we sought to evaluate PAD patient preferences for features of IVIG and SCIg across different patient characteristics. MATERIALS AND METHODS: 119 PAD patients completed a discrete-choice experiment (DCE) survey. The DCE asked respondents to make choices between carefully constructed treatment alternatives described in terms of generic treatment features. Choices from the DCE were analyzed to determine the relative influence of attribute changes on treatment preferences. We used subgroup analysis to evaluate systematic variations in preferences by patients' age, gender, time since diagnosis, and treatment experience. RESULTS: Patients were primarily concerned about the duration of treatment side effects, but preferences were heterogeneous. This was particularly true around administration features. Time since diagnosis was associated with an increase in patients' concerns with the number of needles required per infusion. Also, patients appear to prefer the kind of therapy they are currently using which could be the result of properly aligned patient preferences or evidence of patient adaptive behavior. CONCLUSIONS: Heterogeneity in preferences for Ig replacement treatments suggests that a formal shared decision making process could have an important role in improving patient care.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Front Immunol

DOI

EISSN

1664-3224

Publication Date

2022

Volume

13

Start / End Page

827305

Location

Switzerland

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Surveys and Questionnaires
  • Primary Immunodeficiency Diseases
  • Patient Preference
  • Middle Aged
  • Male
  • Injections, Subcutaneous
  • Infusions, Intravenous
  • Immunoglobulins, Intravenous
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gonzalez, J. M., Ballow, M., Fairchild, A., & Runken, M. C. (2022). Primary Immune Deficiency: Patients' Preferences for Replacement Immunoglobulin Therapy. Front Immunol, 13, 827305. https://doi.org/10.3389/fimmu.2022.827305
Gonzalez, Juan Marcos, Mark Ballow, Angelyn Fairchild, and Michael Chris Runken. “Primary Immune Deficiency: Patients' Preferences for Replacement Immunoglobulin Therapy.Front Immunol 13 (2022): 827305. https://doi.org/10.3389/fimmu.2022.827305.
Gonzalez JM, Ballow M, Fairchild A, Runken MC. Primary Immune Deficiency: Patients' Preferences for Replacement Immunoglobulin Therapy. Front Immunol. 2022;13:827305.
Gonzalez, Juan Marcos, et al. “Primary Immune Deficiency: Patients' Preferences for Replacement Immunoglobulin Therapy.Front Immunol, vol. 13, 2022, p. 827305. Pubmed, doi:10.3389/fimmu.2022.827305.
Gonzalez JM, Ballow M, Fairchild A, Runken MC. Primary Immune Deficiency: Patients' Preferences for Replacement Immunoglobulin Therapy. Front Immunol. 2022;13:827305.

Published In

Front Immunol

DOI

EISSN

1664-3224

Publication Date

2022

Volume

13

Start / End Page

827305

Location

Switzerland

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Surveys and Questionnaires
  • Primary Immunodeficiency Diseases
  • Patient Preference
  • Middle Aged
  • Male
  • Injections, Subcutaneous
  • Infusions, Intravenous
  • Immunoglobulins, Intravenous